Synergy Pharmaceuticals, Inc. (SGYP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence

Synergy Pharmaceuticals, Inc. (SGYP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Synergy Pharmaceuticals, Inc. (SGYP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence
Synergy Pharmaceuticals, Inc. (SGYP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Published Sep 23, 2016
38 pages — Published Sep 23, 2016
Price US$ 250.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Synergy Pharmaceuticals, Inc. (Synergy Pharma), a subsidiary of Pawfect Foods Inc. is a biopharmaceutical company that develops therapies for gastrointestinal diseases and disorders. The company concentrates in therapeutic areas such as chronic idiopathic constipation, opioid-induced constipation, irritable bowel syndrome with constipation and ulcerative colitis. Its products include plecanatide and dolcanatide. Synergy Pharmas plecanatide is a drug candidate, which is used to treat chronic idiopathic constipation and irritable bowel syndrome with constipation. The company develops product based on the natural human hormone. It has a research center in Philadelphia.

Synergy Pharmaceuticals, Inc. (SGYP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharmaceuticals & Healthcare eTrack deals database, and primary and secondary research.


Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.


Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped t

  
Source:
Document ID
GDPH141110D
Country
Industry
Ticker
SGYP=US
Company
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables31
  List of Figures41
Synergy Pharmaceuticals, Inc., Pharmaceuticals &Healthcare, Deals By Year, 2010 to YTD 201642
Synergy Pharmaceuticals, Inc., Pharmaceuticals &Healthcare Deals By Type, 2010 to YTD 201661
Synergy Pharmaceuticals, Inc., Pharmaceuticals &Healthcare, Deals By Region, 2010 to YTD 201671
Synergy Pharmaceuticals, Inc., Pharmaceuticals &Healthcare, Deals By Therapy Area, 2010 to YTD 201681
Synergy Pharmaceuticals, Inc., Pharmaceuticals &Healthcare, Deals Summary, 2010 to YTD 201692
Synergy Pharmaceuticals, Inc., Pharmaceuticals &Healthcare, Deal Details1124
  Asset Purchase111
    Synergy Pharma Acquires FV-100 From Bristol-Myers Squibb112
  Partnerships131
    Bind Therapeutics and Synergy Pharma Enter into Research Agreement131
  Licensing Agreements141
    Synergy Pharma Enters Into Agreement With Ironwood Pharma For Plecanatide141
  Equity Offering151
    Synergy Pharma Raises USD89.8 Million in Private Placement of Shares152
    Synergy Pharma Announces Public Offering Of Shares For Up To US$50 Million171
    Synergy Pharma Completes Public Offering Of Shares For US$90 Million182
    Synergy Pharma Completes Exercise Of Underwriters' Option For Public Offering Of Shares For US$51.75 Million202
    Synergy Pharma Completes Exercise Of Over-Allotment Option For Public Offering Of Units For US$17.25 Million222
    Synergy Pharma Files Registration Statement For Public Offering Of Units For US$0.5 Million241
    Synergy Pharma Completes Private Placement Of Common Stock For US$5.7 Million251
    Synergy Pharma Files Registration Statement For Public Offering Of US$2.5 Million261
    Synergy Pharma Completes Private Placement Of US$0.4 Million271
    Synergy Pharma Completes Private Placement Of US$3 Million282
  Debt Offering301
    Synergy Pharma Raises USD200 Million in Private Placement of 7.5% Notes Due 2019302
  Acquisition321
    Synergy Pharma May Sell Itself321
    Synergy Pharma Completes Acquisition Of Callisto Pharma332
Synergy Pharmaceuticals, Inc. - Key Competitors351
Key Employees361
Locations And Subsidiaries371
  Head Office371
Appendix381
  Methodology381
  About GlobalData381
  Contact Us381
  Disclaimer381

Table Of Contents

About the Author


Cite this Report

  
MLA:
GlobalData Financial Mergers and Acquisitions Intelligence. "Synergy Pharmaceuticals, Inc. (SGYP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile" Sep 23, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Synergy-Pharmaceuticals-Inc-SGYP-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-7761>
  
APA:
GlobalData Financial Mergers and Acquisitions Intelligence. (2016). Synergy Pharmaceuticals, Inc. (SGYP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sep 23, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Synergy-Pharmaceuticals-Inc-SGYP-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-7761>
  
US$ 250.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research